Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000;200(3):196-201.
doi: 10.1159/000018382.

Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis

S Sato  1 , T Nagaoka, M Hasegawa, C Nishijima, K Takehara
Affiliations

Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis

S Sato et al. Dermatology. 2000.

Abstract

Background: Serum KL-6 has been suggested to be a useful marker for the evaluation of interstitial lung disease activity.

Objective: To determine the correlation between serum KL-6 levels and pulmonary fibrosis in patients with systemic sclerosis (SSc).

Methods: Serum samples from patients with limited cutaneous SSc (lSSc; n = 19), diffuse cutaneous SSc (dSSc; n = 26) and normal individuals (n = 15) were examined by ELISA.

Results: Serum KL-6 levels in SSc patients were significantly higher than those in normal controls. KL-6 levels in dSSc patients were significantly elevated compared with those in lSSc patients. Elevated KL-6 levels were associated with the presence of pulmonary fibrosis in SSc patients or dSSc patients. Furthermore, KL-6 levels inversely correlated with percentages of diffusion capacity of carbon monoxide and vital capacity in SSc patients or dSSc patients.

Conclusion: KL-6 may be a simple, serologic indicator for the severity of pulmonary fibrosis in SSc.

PubMed Disclaimer

MeSH terms